Finance

Lists
Why is TRLV down 2.50%?
Dive Deeper
TRLV:NYSE
Trulieve Cannabis Corp ( Delaware )
$10.90
-2.50%
(-0.28) 1D
$11.05
+1.41% (+0.15)
After hours
Closed: Nov 13, 4:00:03 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRLV...
Open
$11.08
High
$11.08
Low
$10.64
Mkt. cap
2.10B
Avg. vol.
1.40M
Volume
1.30M
52-wk high
$12.93
52-wk low
$7.82
EPS
-$2.31
Beta
1.90
Shares outstanding
170.41M
No. of employees
5K
Open
$11.08
High
$11.08
Low
$10.64
Mkt. cap
2.10B
Avg. vol.
1.40M
Volume
1.30M
52-wk high
$12.93
52-wk low
$7.82
EPS
-$2.31
Beta
1.90
Shares outstanding
170.41M
No. of employees
5K
News stories
From web sources and news partners
About Trulieve Cannabis Corp ( Delaware )
CEO-
Employees5K
FoundedSep 14, 1940
HeadquartersTallahassee, Florida, United States
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 4 analysts giving stock ratings to TRLV in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for TRLV in the last 3 months.
Highest
Current $10.90
$20.00 (+83.49%)
Average
$17.25 (+58.26%)
Lowest
$15.00 (+37.61%)
Analyst
Recommendation
Action
Price target
Projected
Date
Bill Kirk
Roth MKM
Buy
Maintained
$19.00
+74.3%
11/06/2026
Frederico Gomes
ATB Cormark Capital Markets
Buy
Maintained
$15.00
+37.6%
11/06/2026
Luke Hannan
Canaccord Genuity
Buy
Reiterated
$20.00
+83.5%
11/06/2026
Unknown Analyst
Cantor Fitzgerald
Buy
Reiterated
$15.00
+37.6%
11/02/2026
Gabrielle Ingoglia
Cantor Fitzgerald
Buy
Reiterated
$15.00
+37.6%
11/02/2026
Neal Gilmer
Haywood
Buy
Reiterated
$17.25
+58.3%
08/07/2026
Aaron Grey
Alliance Global Partners
Buy
Maintained
$20.00
+83.5%
08/07/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
$0.09 / $0.07
+28.57%beat
Revenue / Est. (USD)
230.22M / 221.86M
+3.77%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
293.10M
286.75M
270.95M
230.22M
Cost of goods sold
118.00M
116.67M
108.66M
82.20M
Cost of revenue
118.00M
116.67M
108.66M
82.20M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
126.30M
104.90M
101.77M
87.84M
Operating expense
155.70M
134.64M
127.49M
105.55M
Total operating expenses
273.70M
251.31M
236.15M
187.75M
Operating income
19.40M
35.44M
34.80M
42.47M
Other non operating income
600.00K
132.00K
-403.22M
135.00K
EBT including unusual items
2.90M
25.22M
-383.40M
27.02M
EBT excluding unusual items
8.70M
24.94M
-381.41M
27.01M
Income tax expense
47.90M
21.86M
21.97M
26.25M
Effective tax rate
1,651.72%
86.67%
-5.73%
97.14%
Other operating expenses
-
-
-
-
Net income
-42.90M
2.41M
-405.98M
869.00K
Net profit margin
-14.64%
0.84%
-149.83%
0.38%
Earnings per share
-0.02
0.10
0.11
0.09
Interest and investment income
3.40M
2.68M
3.06M
2.81M
Interest expense
-14.70M
-13.32M
-12.76M
-11.98M
Net interest expenses
-11.30M
-10.64M
-9.70M
-9.16M
Depreciation and amortization charges
29.40M
29.74M
25.72M
17.71M
EBITDA
63.00M
79.18M
73.95M
72.43M
Gain or loss from assets sale
-
-
-
403.33M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps